Kornimate/medical-research-clean huggingface dataset:
"effects of piezocision vs micro-osteoperforations on the rate of maxillary canine retraction

Conditions: Angle Class II, Division 1 Malocclusion

Summary: acceleration of orthodontic tooth movement persuades tremendous rise in the interest of adolescents and aduts, as it not only shortens the treatment duration but also lessens the incidence of white spot lesions, root resorption, periodontal and other soft tissue problems. minimal invasive techniques i.e.both piezocision and micro-osteoperforations had promising results in accelerating tooth movement. therefore current study will provide evidence for better minimal invasive technique in terms of reducing treatment time and patient comfort.

patients with angle's class ii division 1 malocclusion meeting selection criteria and are indicated for maxillary first premolar extraction, patients will be referred for extraction of the maxillary first premolars , treatment will be initiated by bonding preadjusted mbt 0.022" slot straight wire appliance(patient will be instructed to report immediately in case of breakage of appliance), after that, leveling and alignment will be done in all subjects, after insertion of 0.019"× 0.025" stainless steel arch wire, alginate impression and periapical radiograph of canine and first molar region will be taken(before the initiation of canine retraction), randomisation and allocation of two sides of maxillary arch i.e. right and left will be done and active interventions(piezocision and micro-osteoperforations) for each side will be done, immediately maxillary canine retraction will be started with mini-implant and closed niti coil spring, patient will be asked to fill pain and discomfort assessment card immediately after initiation of canine retraction., subsequent impressions records will be taken at 4th, 8th, 12th and 16th weeks for measuring rate of maxillary canine retraction, data collection and interpretation of results, further pain assessment cards will be filled after 24 hours, on 7th day and 28th day

Eligibility criteria:
inclusion criteria: 1. patients with age between 16-25 years 2. patients with angle's class ii division 1 malocclusion requiring bilateral extraction of maxillary first premolars. 3. overjet of ≤ 10mm 4. no debilitating systemic disease. 5. no radiographic evidence of bone loss. 6. no history of periodontal disease/ therapy. 7. no smoking habit. 8. probing depth of not more than 3mm in all teeth. exclusion criteria: 1. presence of any signs and symptoms of gingival and periodontal diseases. 2. overjet more than 10mm. 3. long-term drug history. 4. systemic diseases. 5. evidence of bone loss. 6. smoking habit.
gemcitabine and oxaliplatin (gemox) in first line metastatic or recurrent nasopharyngeal carcinoma

Conditions: Nasopharyngeal Neoplasms

Summary: primary objective: to evaluate the response rate of biweekly gemcitabine and oxaliplatin (the gemox regimen) in the first line treatment of metastatic or recurrent nasopharyngeal carcinoma. secondary objectives: to assess the toxicity, duration of response, time to progression, progression-free survival, overall survival and cancer-related symptoms in the first line treatment of patients with metastatic or recurrent npc.


Eligibility criteria:
inclusion criteria: * patients with histologically or cytologically proven nasopharyngeal carcinoma (npc) with metastatic or recurrent disease that is not amenable to potentially curative surgery or radiotherapy. they must not have prior chemotherapy for the treatment of metastatic or recurrent disease. * prior neoadjuvant, adjuvant or concurrent chemotherapy is allowed as long as a minimum period of 6 weeks has elapsed since the last day of treatment. this includes the use of carboplatin or cisplatin. * patients must have at least one uni-dimensional measurable lesion (according to recist criteria) * prior rt or surgery to the target lesion(s) is allowed as long as there is documented disease progression within the rt/ surgical field, and a minimum period of 6 weeks has elapsed since the last day of treatment. * eastern cooperative oncology group performance status of 0-2 * no serious, uncontrolled medical conditions that may be aggravated by treatment. * no other malignancy(s), except completely excised basal or squamous cell carcinoma of the skin, or completely treated carcinoma-in-situ of the cervix. * adequate hematological function:absolute granulocyte count \> 1.5 x 10\^9/l, platelet count \> 100 x 10\^9/l * adequate renal and hepatic functions:·serum creatinine \ 50 ml/min·serum bilirubin \< 2 x unl and aspartate aminotransferase/alanine aminotransferase \< 3 x unl exclusion criteria: * prior treatment with oxaliplatin or gemcitabine. * patients who have persistent grade 2 or more sensory and/or motor neuropathy, or ototoxicity resulting from prior cisplatin/ carboplatin. * active or past history of central nervous system metastasis from the primary tumor * potentially life-threatening infections * patients have used any investigational drug treatment in the month prior to inclusion. * pregnancy or not exercising appropriate birth control during the course of the study. breast-feeding women the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
clinical significance of occult central nervous system localization

Conditions: Acute Lymphoblastic Leukemia

Summary: in acute lymphoblastic leukemia (all), the occult central nervous system (cns) involvement appears to be associated with poor prognosis. flow cytometry (fcm) allows detection of occult cns localization. the current international guidelines do not recommend the use of fcm in the assessment of cns at onset in adult all patients. large-scale prospective studies will help to clarify whether or not patients with occult cns localization should undergo cns-directed therapy. understanding this seems particularly important nowadays considering that with the introduction of new drugs (monoclonal antibodies, next-generation tyrosine kinase inhibitors, car-t) the therapeutic approach of patients with als is increasingly "chemo-free"

the investigators propose a multicenter prospective study to evaluate the incidence of occult cns localization and the impact of such localization on clinical outcome.adult all patients routinely undergo diagnostic lumbar puncture (pl); cerebrospinal fluids (csf )samples will be studied by investigation of conventional cytology (cc) and fcm at the time of the first and subsequent diagnostic pls.

Eligibility criteria:
inclusion criteria. * patients aged more than18 years with diagnosis of all at onset undergoing diagnostic-therapeutic pl. * signed written informed consent in accordance with ich/eu/gcp guidelines and national and local laws. exclusion criteria. * patients \<18 years of age * diagnosis other than all * inability to perform pl
capacity assessment in persons with alzheimer's disease

Conditions: Alzheimer's Disease; Capacity to Consent to Treatment; Capacity to Vote; Capacity to Design a Proxy

Summary: the purpose of this study is to assess decision-making capacity in persons with alzheimer's disease. first, our goal is to validate four french capacity assessment tools for persons with alzheimer's disease : a french version of the competency assessment tool for consent to treatment and of the competency assessment tool for voting, two questionnaires assessing the capacity to appoint a proxy either to consent to treatment or to vote. second, once validated, we plan these questionnaires to study decision-making abilities and their determinants in persons with alzheimer's disease and control subjects.

study of alzheimer's disease patients show a wide variability in decision-making abilities, especially for the consent to treatment and the ability to vote. no tools are available to assess the capacity to design a proxy. the purpose of this research is to assess simultaneously four decision-making abilities in persons with alzheimer's disease: the capacity to consent to treatment, the capacity to vote and the capacity to design a proxy either to consent to treatment or to vote. this study will recruit 320 patients with alzheimer's disease and 80 non-demented control subjects. four decision-making questionnaires will be administered to participants to explore participant capacity to understand, reason, appreciate and make a choice about the capacity to consent to treatment, to vote and to design a proxy either to consent to treatment or to vote. once validated in the first part of this research, the questionnaires will be used to study decision-making abilities and their determinants in patients with alzheimer's disease and control subjects.

Eligibility criteria:
inclusion criteria: * for patients with alzheimer's disease: age \>=18 years, to be native speakers of french and french nationality, diagnosed with a alzheimer's disease and followed in a french "centre memory of resources and research"(cmrr) * for control subjects: age \>=18 years, to be native speakers of french and french nationality, have no complaints of memory problems, primary caregiver of patient with ad of the same age as the patient nearly 10 years exclusion criteria: * for all participants: confusion, severe psychiatric disorders, stroke, blindness, uncorrected hearing loss, refusal to participate in the study * for patients with alzheimer's disease: other dementia than ad * for control subjects: diagnosed dementia

Keywords: alzheimer's disease capacity assessment decision-making assessment capacity to consent to treatment capacity to vote capacity to appoint a proxy
pelvic floor muscle training and kaatsu training for women with stress urinary incontinence

Conditions: Urinary Stress Incontinence

Summary: this study examines the effect of adding so called kaatsu training to pelvic floor muscle training. half the participants will perform kaatsu training on their thigh muscles followed by pelvic floor muscle training. the other half will receive pelvic floor muscle training alone.

stress urinary incontinence (su) is a common problem among adult women . pelvic floor muscle training (pfmt) is recommended as first line treatment but pfmt is not always efficient and some women cannot comply with the intensive pfmt needed to obtain effect because of weakened or damaged muscles caused by vaginal delivery and age related changes. hypothetically alternative methods could be used to enhance the effect of a strength-training program. a low intensity training program with a simultaneous partial occlusion of the blood supply for the training muscle, so called "kaatsu" training has been found to increase muscle strength faster than ordinary strength training but with much less effort. it seems difficult to make occlusion of the pelvic floor muscles during pfmt but a study found that low intensity training of the quadriceps femoris with partial occlusion of the blood supply did not only increase muscle strength of the quadriceps femoris muscle but also of the biceps humeri muscle if that muscle was trained with low-load training and no occlusion in the same training session. the specific reason for this this "cross-transfer effect" could not be fully explained but it was believed to be caused by a systemic effect caused by growth hormones. the aim of this study is therefore to examine if kaatsu training offered in relation to a low-load pfmt program can increase the effect of pfmt in women with sui

Eligibility criteria:
inclusion criteria: * iciq-sf ≥ 12 * urinary stress incontinence * ability to contract pelvic floor muscles * normal bladder capacity and normal flow during micturition with at least one micturition of \> 350 ml exclusion criteria: * urgency urinary incontinence * cognitive problems * physical inability to perform kaatsu program * inability to understand and read danish

Keywords: urinary stress incontinence pelvic floor muscle kaatsu training
quality of erection study

Conditions: Erectile Dysfunction

Summary: the study objective is to evaluate the effect that sildenafil citrate has on the hardness of erections in males with erectile dysfunction, based on subject responses to question 5 on the event log (hardness of erection) as measured at the end of double blind treatment (week 6).


Eligibility criteria:
inclusion criteria: * male subjects aged 18-55 * documented clinical diagnosis of erectile dysfunction confirmed by an iief-ef domain score of less than or equal to 25. (if the subject scores greater than 25 on the iief-ef domain, screening procedures should be terminated.) exclusion criteria: * subjects who have been treated with more than 6 doses of sildenafil citrate or any other phosphodiesterase type 5 (pde-5) inhibitor such as vardenafil or tadalafil for erectile dysfunction \[note: subjects should not have taken any pde-5 inhibitors within 4 weeks prior to the date of screening\]

Keywords: impotence
anti-leukemic dendritic cell activated donor lymphocytes

Conditions: Leukemia, Myelocytic, Acute

Summary: objectives: 1. determine the toxicity of infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (dc/adl) in relapsed patients after allo-stem cell transplants. 2. quantitate the alloreactivity of dc/adl and circulating immune effector cells in patients after infusion. 3. assess efficacy of acute myelogenous leukemia (aml) or chronic myelogenous leukemia in blastic crisis (cml-bc) derived dendritic cells and activated lymphocytes in promoting and sustaining remission in patients with relapse after allo-bmt or stem cell transplant.


Eligibility criteria:
inclusion criteria: * aml (any type except m3) or civil in blast crisis with greater than or equal to 20% bone marrow blasts at the time of related donor marrow or stem cell transplantation or at relapse post transplant. * willing to undergo a skin biopsy and either a leukodepletion apheresis or an additional marrow aspiration. * stem cell or marrow donor willing to have apheresis for t-cell collection. * written voluntary informed consent must be obtained from patient and donor. exclusion criteria: * medical, social or psychologic factors which would prevent the patient from receiving or cooperating with the full course of therapy or understanding the informed consent procedure. * aml french-american-british (fab) subtype m3.

Keywords: dendritic cells lymphocytes aml
naproxen sodium extended-release actual use study

Conditions: Pain

Summary: the purpose of this study is to assess how subjects will use the investigational product in an uncontrolled, naturalistic environment.

issues on adverse event data are addressed in the adverse event section. the following acronyms and abbreviations were used in the results section. - general educational development (ged)

Eligibility criteria:
inclusion criteria: * self report use of over the counter (otc) analgesics * able to read and understand english * provide written informed consent (subjects 12- 17 years of age provide written as sent and/ or parent or legal guardian provide written consent) * purchase the investigational product exclusion criteria: * have participated in a study involving otc analgesics in the last 12 months * they or someone else in the household work for a market research company, an advertising agency, a public relations firm, pharmaceutical company, as a healthcare professional, or as part of a health care practice * have a history of known allergies to nonsteroidal anti-inflammatory drugs (nsaids) (i.e., naproxen, ibuprofen, etc) or aspirin * have a history of heart surgery in the last 60 days or plans for heart surgery in the next 60 days * (female subjects) are pregnant or breastfeeding

Keywords: non-prescription
quality of life impact of nasal airway treatment with aerin medical device

Conditions: Nasal Obstruction

Summary: evaluation of long-term (5-year) quality of life after nasal airway obstruction treatment with the aerin vivaer stylus

this is a prospective, non-randomized, multi-center follow-up study to collect long term quality of life (qol) data on a cohort of patients who participated in the aerin medical tp258 study "a prospective, multi-center, non-randomized study to evaluate treatment of nasal airway obstruction using the aerin medical device". the tp258 study followed subjects out to 26 weeks post-procedure. this qol study will collect data at 12, 18, 24, 36, 48 and 60 months post-procedure.

Eligibility criteria:
inclusion criteria: * received nasal obstruction treatment in aerin study tp 258 exclusion criteria: * unwilling to participate in this long-term study

Keywords: nasal valve nasal airway obstruction quality of life
safety and efficacy study of retreated clevudine in chronic hbv patients who received clevudine in l-fmau-201

Conditions: Hepatitis B

Summary: the purpose of this study is to determine the safety and antiviral activity of clevudine, when retreated to patients previously treated with clevudine


Eligibility criteria:
inclusion criteria: 1. patients who received clevudine in l-fmau-201 clinical trial (phase iib) 2. female of childbearing potential must have a negative serum ( b-hcg) pregnancy test within 14 days of starting therapy. 3. patient is able to give written informed consent prior to study start and to comply with the study requirements. 4. patients who met the following criteria after completion of the week 48 visit were to have additional follow-up visits at weeks 54 and 60: 1) had received no additional therapy since completion of 24-week treatment of clevudine and 2)experienced a \> 1 log10 decrease from baseline in hbv dna at week 48 exclusion criteria: 1. hbv dna negative (\< 4,700 copies/ml) consistently at the last 2 visit (at least 2 consecutive visits, at one month interval) 2. patient is currently receiving antiviral immunomodulatory or corticosteroid therapy. 3. patients previously treated with lamivudine, lobucavir, adefovir or any other investigational nucleoside for hbv infection after cessation of treatment in l-fmau-201 study. 4. patient has a history of ascites, variceal hemorrhage or hepatic encephalopathy. 5. patient is coinfected with hcv, hdv or hiv. 6. patient with clinical evidence of cirrhosis or hepatocellular carcinoma (®-fetoprotein) evaluation will be based on alpha-fetoprotein primarily. if alpha-fetoprotein level is suggestive of cirrhosis or hepatocellular carcinoma, confirmation will be made with sonography etc. 7. patient is pregnant or breast-feeding. 8. patient is unwilling to use an "effective" method of contraception during the study and for up to 3 months after the use of study drug ceases. for males, condoms should be used. females must be surgically sterile (via hysterectomy or bilateral tubal ligation), post-menopausal or using at least a medically acceptable barrier method of contraception (i.e., iud, barrier methods with spermicide or abstinence) 9. patient has a clinically relevant history of abuse of alcohol or drugs. 10. patient has a significant gastrointestinal, renal, hepatic (decompensated), bronchopulmonary, neurological, cardiovascular, oncologic or allergic disease. 11. patient has creatinine clearance less than 60ml/min as estimated by the following formula: (140-age in years) (body weight \[kg\])/(72) (serum creatinine \[mg/dl\]) \[note: multiply estimates by 0.85 for women\]
the relationship between serum gasdermin-d levels and pyroptosis and preterm labor

Conditions: Gasdermin D Levels in Preterm Labor

Summary: in this study, the investigators aimed to investigate the relationship between gasdermin d levels measured from the maternal serum of patients diagnosed with preterm labor and spontaneous preterm labor in pregnant women.

this prospective case- control study was conducted between 15 july 2021 and 15 july 2022 at bursa yüksek i̇htisas training and research hospital. the study was conducted with pregnant women between the ages of 18-45 who were idiopathic preterm labor. pregnant women between the ages of 18-45 who were diagnosed with preterm labor between 24-37 weeks of gestational were included. this study was conducted with 160 pregnant women who were diagnosed with idiopathic preterm labor and 167 healthy pregnant women who were in the same gestational week as these pregnant women and were not diagnosed with preterm labor. group 1 patients diagnosed with preterm labor between 24-37 weeks( study group) (n:160), group 2 consisted of healthy pregnant women who were not diagnosed with preterm labor between 24-37 weeks ( control group) (n: 167) . in group 1, 80 patients were diagnosed with early preterm (between 24-34 weeks ) and 80 patients with late preterm labor (34-36+6 weeks).

Eligibility criteria:
inclusion criteria: * pregnant women who were diagnosed with idiopathic preterm labor and gave birth in our hospital * pregnant women without vaginal infection * healthy pregnant women between 24-37 weeks without a diagnosis of preterm labor exclusion criteria: * multiple pregnancies * pregnant women with a prediagnosis of chromosomal and congenital anomalies in the fetus * women with a known infective or autoimmune disease before pregnancy

Keywords: gasdermin d preterm labor pyroptosis
a multinational, open-label, non-controlled trial on safety, efficacy and pharmacokinetics of nnc 0129-0000-1003 in previously treated paediatric patients with severe haemophilia a

Conditions: Congenital Bleeding Disorder; Haemophilia A

Summary: this trial is conducted globally. the aim of the trial is to investigate safety, efficacy and pharmacokinetics (the exposure of the trial drug in the body) of nnc 0129-0000-1003 (n8-gp) in children with severe haemophilia a who have undergone treatment with previous factor viii (fviii) products.


Eligibility criteria:
inclusion criteria: * male patients with severe congenital haemophilia a (fviii activity level below 1%) * weight above or equal to 10 kg - documented history of 150 exposure days (ed) to fviii products for patients aged 6-11 years and above 50 ed to fviii products for patients aged 0-5 years exclusion criteria: - any history of fviii inhibitors